Physician profile
Everardo Lopez
NPI 1851379572
$599.51
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $85.78 · 2021: $114.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $114.41 | 2021 | |
| Lilly USA, LLC | $86.89 | 2019-2020 | |
| Novo Nordisk INC | $84.88 | 2019-2020 | |
| Allergan, INC. | $63.70 | 2019-2020 | |
| Glaxosmithkline, LLC. | $54.49 | 2019-2020 | |
| Amgen INC. | $52.48 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $29.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.03 | 2019 | |
| Merck Sharp & Dohme LLC | $24.39 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.57 | 2019 | |
| Amarin Pharma, INC. | $12.81 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Everardo Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.